TILT Biotherapeutics

TILT Biotherapeutics Ltd. is a global leader in oncolytic virus therapies for tumor T-cell treatments. TILT is a preclinical stage company in the field of cancer immunotherapy, which will soon translate its unique approach into clinical trials. The company's patented technology involves the use of oncolytic viruses to enhance tumor T-cell therapy. The initial implementation of this technology will be used to augment tumor-infiltrating lymphocytes (TIL), chimeric antigen receptor T-cell (CAR-T), and checkpoint inhibitor antibody treatments. The TILT approach has the potential to achieve results in CAR-T treatments for solid tumors similar to those currently seen in CD19+ blood cancers.